



THC BIOMED INTL LTD.  
P.O. Box 20033 Towne Centre  
Kelowna, B.C. V1Y 9H2  
[www.thcbiomed.com](http://www.thcbiomed.com)

---

**THC Receives New License Under *Cannabis Act***

**Clone Shipper Obtains U.S. Patent and Trademark Office Allowance**

**THC Makes 4th delivery of cannabis products to Province of B.C.**

**Continues to Expand Grow Space**

---

**CSE.THCH**

**OTC.THCBF**

**F.TFHC**

**Vancouver, BC – (November 14, 2018)** THC BioMed Intl Ltd. (“THC” or the “Company”) (CSE: THCH) announces that it has received a *Cannabis Act* and *Cannabis Regulations* License from Health Canada on November 8, 2018. This is the new license under the *Cannabis Act* and it allows THC to grow, produce and sell cannabis products on a large scale under the new regime.

THC is also very pleased to announce that Clone Shipper, its wholly-owned subsidiary, has received a Notice of Allowance from the U.S. Patent and Trademark Office regarding THC’s patent application for the invention of an illuminated shipping container for live cannabis plants. THC now has three months to conduct a final review of its patent application, file any necessary amendments, submit the formal drawings and pay the Issue fee. The Notice of Allowance is not a grant of patent rights but a notice from the Examiner that the Application is being allowed.

In addition, due to the high demand for our cannabis products, THC has completed its fourth (4<sup>th</sup>) shipment of cannabis products to the Province of B.C. Its previous three shipments have sold out since launch day on October 17, 2018.

THC is focused on meeting the high demand for its products. It continues to expand and develop its production space, as announced in previous press releases on October 16, 2018, June 29, 2018, June 12, 2018 and earlier.

**About THC**

THC's vision is to be on the leading edge of scientific research, development of products and services related to the medical cannabis industry while creating a standard of excellence. As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry.

Please visit our website for a more detailed description of our business and services available.  
[www.thcbiomed.com](http://www.thcbiomed.com)

**President and CEO:**

John Miller  
THC Biomed Intl Ltd.  
T: 1-844-THCMEDS  
E: [info@thcbiomed.com](mailto:info@thcbiomed.com)

**Forward-Looking Information:**

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. In some cases, you can identify forward-looking statements by the use of words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release include that THC will expand and develop its grow space. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

***The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.***